吉泊达星（Gepotidacin）的药理学与治疗学见解：一种首创的三氮杂苊烯类抗生素。
完整摘要 · 中文译文
抗菌药物耐药性日益严峻的挑战迫使人们开发具有新作用机制的新型抗生素。Gepotidacin是一种首创的三氮杂苊烯类抗生素，用于治疗成年女性及青少年无并发症尿路感染（uUTIs）。它通过与氟喹诺酮类不同的结合位点同时靶向DNA旋转酶和拓扑异构酶IV，从而抑制细菌DNA复制，因此呈现一种新的作用机制。然而，影响敏感性的耐药相关突变已有记录，强调需要持续监测。药代动力学研究表明，其口服吸收可预测且呈剂量依赖性，适合每日两次或三次给药，累积极少，且各人群间的药代动力学特征相当。在治疗uUTIs的疗效方面，III期临床试验（EAGLE-2和EAGLE-3）表明，在EAGLE-2中gepotidacin不劣于广谱抗生素呋喃妥因，在EAGLE-3中甚至优于呋喃妥因，其耐受性与同类其他抗生素相当。研究还提示其对无并发症淋病（GC）可能有效，包括对现有疗法耐药的菌株。不良事件通常为轻度至中度，主要为胃肠道反应，对有QT间期延长风险的患者建议慎用。尽管gepotidacin为这些感染本已有限的现有口服抗生素库增添了重要选择，但其长期临床效用将取决于…… 最终依赖于谨慎的管理、耐药性监测以及在更广泛的适应症和联合方案中的进一步评估。
完整摘要 · 英文原文
The growing challenge of antimicrobial resistance has necessitated the development of new antibiotics with novel mechanisms of action. Gepotidacin is a first-in-class triazaacenaphthylene antibiotic developed for the treatment of uncomplicated urinary tract infections (uUTIs) in female adults and adolescents. It inhibits bacterial DNA replication by targeting both DNA gyrase and topoisomerase IV at a distinct binding site, differing from fluoroquinolones and therefore presenting a novel mechanism of action. However, resistance-associated mutations affecting susceptibility have been documented, emphasizing the need for ongoing monitoring. Pharmacokinetic studies indicate predictable, dose-dependent oral absorption suitable for twice- or thrice-daily dosing, with minimal accumulation and comparable profiles across populations. In terms of therapeutic success for the treatment of uUTIs, phase III clinical trials (EAGLE-2 and EAGLE-3) have demonstrated that gepotidacin was non‑inferior to the broad-spectrum antibiotic nitrofurantoin in EAGLE-2 and even superior to nitrofurantoin in EAGLE-3, with a tolerability profile comparable to other antibiotics of its class. Studies also suggest potential efficacy against uncomplicated gonorrhea (GC), including strains resistant to current therapies. Adverse events were generally mild to moderate, predominantly gastrointestinal, and caution is advised in patients with QT prolongation risk. While gepotidacin represents an important addition to the limited pool of oral antibiotics for these infections, its long-term clinical utility will depend on careful stewardship, resistance surveillance, and further evaluation in broader indications and combination regimens.